SEC Form 4 · accession 0001214659-17-007028
NEXIEN BIOPHARMA, INC. · NXEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Evan L Wasoff
Officer — Chief Financial Officer
Period of report
Nov 29, 2017
Accepted (ET)
Nov 30, 2017 · 1:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001625288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 29, 2017 | J | 629,128 | — | A | 1,000,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As adjusted to reflect a one-for-six reverse split of the issuer's common stock effective November 29, 2017
- F2Acquired in exchange for all of Evan Wasoff's shares of Intiva BioPharma Inc.